These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36920664)

  • 1. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
    Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
    Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Hertler C; Felsberg J; Gramatzki D; Le Rhun E; Clarke J; Soffietti R; Wick W; Chinot O; Ducray F; Roth P; McDonald K; Hau P; Hottinger AF; Reijneveld J; Schnell O; Marosi C; Glantz M; Darlix A; Lombardi G; Krex D; Glas M; Reardon DA; van den Bent M; Lefranc F; Herrlinger U; Razis E; Carpentier AF; Phillips S; Rudà R; Wick A; Tabouret E; Meyronet D; Maurage CA; Rushing E; Rapkins R; Bumes E; Hegi M; Weyerbrock A; Aregawi D; Gonzalez-Gomez C; Pellerino A; Klein M; Preusser M; Bendszus M; Golfinopoulos V; von Deimling A; Gorlia T; Wen PY; Reifenberger G; Weller M
    Eur J Cancer; 2023 Aug; 189():112913. PubMed ID: 37277265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
    Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
    Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
    Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
    Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients.
    Radke J; Koch A; Pritsch F; Schumann E; Misch M; Hempt C; Lenz K; Löbel F; Paschereit F; Heppner FL; Vajkoczy P; Koll R; Onken J
    Acta Neuropathol Commun; 2019 Jun; 7(1):89. PubMed ID: 31167648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptional diversity of long-term glioblastoma survivors.
    Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
    Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.